Studies from Leidos Biomedical Research Inc. Yield New Information about Noonan Syndrome (Ras-dependent Raf-mapk Hyperactivation By Pathogenic Rit1 Is a Therapeutic Target In Noonan Syndrome-associated Cardiac Hypertrophy).

Zdroj:	Drug Week; 9/15/2023, p1197-1197, 1p
Abstrakt:	Consistent with aberrant RAF/MAPK activation as a driver of disease, we show that pathway inhibition alleviates cardiac hypertrophy in a mouse model of RIT1 mutant Noonan syndrome." Keywords: Frederick; State:Maryland; United States; North and Central America; Biomedical Companies; Business; Cardiology; Cardiomegaly; Congenital Abnormalities; Craniofacial Abnormalities; Craniofacial Diseases and Conditions; Drugs and Therapies; Health and Medicine; Heart Disorders and Diseases; Hypertrophy; Musculoskeletal Abnormalities; Musculoskeletal Diseases and Conditions; Noonan Syndrome; Skin and Connective Tissue Diseases and Conditions EN Frederick State:Maryland United States North and Central America Biomedical Companies Business Cardiology Cardiomegaly Congenital Abnormalities Craniofacial Abnormalities Craniofacial Diseases and Conditions Drugs and Therapies Health and Medicine Heart Disorders and Diseases Hypertrophy Musculoskeletal Abnormalities Musculoskeletal Diseases and Conditions Noonan Syndrome Skin and Connective Tissue Diseases and Conditions 1197 1197 1 09/11/23 20230915 NES 230915 2023 SEP 11 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Fresh data on Musculoskeletal Diseases and Conditions - Noonan Syndrome are presented in a new report. [Extracted from the article]
Databáze:	Supplemental Index
Externí odkaz:	Zobrazit plný text záznamu